Forward Price-to-Revenue Multiple: CVRx, Inc. (CVRX)

Brandmark of CVRx Inc (CVRX)

The uniqueness of the Barostim system provides CVRx, Inc. (CVRX) with strong pricing power. The forward P/S multiple reflects the current market valuation, where the 0.30 mark indicates the analyst consensus level. While neurostimulator patents create a steady cash flow, slow physician adoption and reliance on insurance reimbursements limit the company's revenue growth potential.

CVRx Inc. - CVRX Forward Price-to-Revenue Multiple (period 07/04/2022 - 11/13/2026)

Comprehensive metric breakdowns and analytics for CVRx Inc (CVRX)

- current price and projected stock value:
Stock Price CVRx|CVRX - Consensus Target
- company stock exchange capitalization indicators:
Market Valuation CVRx Inc|CVRX - Company Buyout Price
- business book valuation details:
Book Value per Share CVRx, Inc.|CVRX - Company Net Assets|Market Cap to Net Assets Ratio cvrx.com|CVRX - Aggregate Company Assets
- company liabilities and liquidity data:
Debt to Equity CVRx, Inc.|CVRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio CVRx, Inc.|CVRX - Company Aggregate Debt|Debts to Book Capitalization CVRx Inc|CVRX - Company Long-Term Loans and Borrowings|Company Short-Term Debts CVRx, Inc.|Quick Ratio cvrx.com
- financial results and valuation multiples details:
CVRX - Net Profit|Expected Profit CVRx, Inc.|CVRX - Company Value to Net Income|Projected Price to Earnings CVRx, Inc|CVRX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple CVRx Inc|CVRX - Operating profit before deduction of amortization|Net earnings per share for the last 12 months CVRx, Inc.|CVRX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months cvrx.com|CVRX - Earnings per share increase in current year|Expected earnings per share growth for next year CVRx, Inc.
- sales and revenue data:
CVRX - Company Sales Volume|Company Future Sales Volume CVRx|CVRX - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple CVRx Inc
Fundamental company valuation:CVRx CVRX
Original product of cvrx.com

Utilizing the forward P/S metric minimizes the risk of capital undervaluation, allowing for a correlation between the current market value of CVRx, Inc. (CVRX) and expected revenue volumes. The integration of Barostim therapy into clinical protocols through partnerships with cardiologists directly impacts future sales, which is reflected in the trend of this forward P/S metric. Investors can observe the real-time sensitivity of market capitalization to product commercialization rates, eliminating the time lags associated with quarterly reporting.

Key competitors

Forward P/S Multiple REGN (Regeneron)|IRTC - Forward Price-to-Revenue Multiple|LNTH: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Mineralys Corp MLYS|HTFL: Forward P/S Multiple|Forward Price-to-Revenue Multiple kestramedical.com|Forward Price-to-Revenue Multiple ESPR|Price-to-Projected Revenue Ratio AMRN|Price-to-Projected Revenue Ratio Anteris Technologies Global (AVR)|TNYA (tenayatherapeutics.com) - Forward Price to Sales|Milestone Pharmaceuticals - Forward Price-to-Revenue Multiple|CRDL: Market Cap to Projected Revenue|HeartBeam - Forward P/S Multiple|Forward Price to Sales TENX (Tenax Therapeutics Inc.)|ADGM: Forward P/S Multiple|Market Cap to Future Revenue Ratio BioCardia Inc (BCDA)|VTAK (Catheter Precision) - Forward P/S Multiple|Forward P/S Multiple ARCA Bio|Price-to-Projected Revenue Ratio Acasti Pharma (ACST)|AVTE (Aerovate Therapeutics Inc.) - Forward Price to Sales|Verve Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio WINT (Windtree Therapeutics Inc.)